Patents by Inventor Ilaria TASSI
Ilaria TASSI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240076362Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: May 1, 2023Publication date: March 7, 2024Inventors: Jeonghoon SUN, Wei-Hsien HO, Muhammad A. ALHAWAGRI, Philip Ling KONG, Herve RHINN, Hua LONG, Karpagam SRINIVASAN, Ananya MITRA, Daniel P. BERMINGHAM, Klaus-Dieter HEGER, Santiago Viveros SALAZAR, Francesca CIGNARELLA, Ilaria TASSI, Tina SCHWABE, Angie Grace YEE, Arnon ROSENTHAL
-
Publication number: 20230312712Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: February 24, 2023Publication date: October 5, 2023Applicant: Alectro LLCInventors: Tina SCHWABE, Eric BROWN, Philip KONG, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL, Robert PEJCHAL, Nels P. NIELSON
-
Publication number: 20230295297Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: February 17, 2023Publication date: September 21, 2023Applicant: Alector LLCInventors: Tina SCHWABE, Fracesca AVOGADRI-CONNORS, Helen LAM, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL
-
Patent number: 11667699Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: July 30, 2020Date of Patent: June 6, 2023Assignee: Alector LLCInventors: Jeonghoon Sun, Wei-Hsien Ho, Muhammad A. Alhawagri, Philip Ling Kong, Herve Rhinn, Hua Long, Karpagam Srinivasan, Ananya Mitra, Daniel P. Bermingham, Klaus-Dieter Heger, Santiago Viveros Salazar, Francesca Cignarella, Ilaria Tassi, Tina Schwabe, Angie Grace Yee, Arnon Rosenthal
-
Publication number: 20230159637Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.Type: ApplicationFiled: February 23, 2021Publication date: May 25, 2023Applicants: Alector LLC, Washington UniversityInventors: Francesca CIGNARELLA, Fabia FILIPELLO, Bryan BOLLMAN, Arnon ROSENTHAL, Tina SCHWABE, Ilaria TASSI, Laura PICCIO
-
Publication number: 20230142579Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: August 19, 2022Publication date: May 11, 2023Inventors: Philip KONG, Herve RHINN, Tina SCHWABE, Angie YEE, Ilaria TASSI, Muhammad Abbas ALHAWAGRI, Arnon ROSENTHAL
-
Publication number: 20230126400Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc.. that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: August 19, 2022Publication date: April 27, 2023Inventors: Philip KONG, Herve RHINN, Tina SCHWABE, Angie YEE, Ilaria TASSI, Muhammad Abbas ALHAWAGRI, Arnon ROSENTHAL
-
Patent number: 11634489Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: March 30, 2020Date of Patent: April 25, 2023Assignee: Alector LLCInventors: Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
-
Publication number: 20230107639Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.Type: ApplicationFiled: April 21, 2022Publication date: April 6, 2023Applicant: Alector LLCInventors: Kate MONROE, Tina SCHWABE, Francesca AVOGADRI-CONNORS, Ilaria TASSI, Helen LAM, Arnon ROSENTHAL
-
Publication number: 20230024528Abstract: The present disclosure is generally directed to the use of anti-TREM2 antibodies in preventing, reducing risk, or treating disease in an individual in need thereof.Type: ApplicationFiled: December 4, 2020Publication date: January 26, 2023Applicant: Alector LLCInventors: Tina SCHWABE, Ilaria TASSI, Arnon ROSENTHAL, Hua LONG, Santiago Viveros SALAZAR
-
Patent number: 11472874Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: January 31, 2019Date of Patent: October 18, 2022Assignee: Alector LLCInventors: Philip Kong, Herve Rhinn, Tina Schwabe, Angie Yee, Ilaria Tassi, Muhammad Abbas Alhawagri, Arnon Rosenthal
-
Patent number: 11470827Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from TREM1, TREML1, TREM2, TREML2, and TREML4, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human TREM immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human TREM repertoire.Type: GrantFiled: December 12, 2018Date of Patent: October 18, 2022Assignee: Alector LLCInventors: Ilaria Tassi, Asa Abeliovich, Seung-Joo Lee, Arnon Rosenthal, Tina Schwabe
-
Patent number: 11084875Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.Type: GrantFiled: April 11, 2019Date of Patent: August 10, 2021Assignee: ALECTOR LLCInventors: Kate Monroe, Tina Schwabe, Francesca Avogadri-Connors, Ilaria Tassi, Helen Lam, Arnon Rosenthal
-
Publication number: 20210079074Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, humanized antibodies and antibody fragments, that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: July 30, 2020Publication date: March 18, 2021Inventors: Jeonghoon SUN, Wei-Hsien HO, Muhammad A. ALHAWAGRI, Philip Ling KONG, Herve RHINN, Hua LONG, Karpagam SRINIVASAN, Ananya MITRA, Daniel P. BERMINGHAM, Klaus-Dieter HEGER, Santiago Viveros SALAZAR, Francesca CIGNARELLA, Ilaria TASSI, Tina SCHWABE, Angie Grace YEE, Arnon ROSENTHAL
-
Publication number: 20210040200Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MS4A4A polypeptide, e.g., a mammalian MS4A4A or human MS4A4A, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: January 31, 2019Publication date: February 11, 2021Inventors: Philip KONG, Herve RHINN, Tina SCHWABE, Angie YEE, Ilaria TASSI, Muhammad Abbas ALHAWAGRI, Arnon ROSENTHAL
-
Publication number: 20200317776Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: March 30, 2020Publication date: October 8, 2020Applicant: Alector LLCInventors: Tina SCHWABE, Eric BROWN, Philip KONG, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL, Robert PEJCHAL, Nels P. NIELSON
-
Patent number: 10676525Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: GrantFiled: August 3, 2018Date of Patent: June 9, 2020Assignee: ALECTOR LLCInventors: Tina Schwabe, Eric Brown, Philip Kong, Ilaria Tassi, Seung-Joo Lee, Arnon Rosenthal, Robert Pejchal, Nels P. Nielson
-
Publication number: 20190330335Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 or human TREM2, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.Type: ApplicationFiled: October 6, 2016Publication date: October 31, 2019Applicant: ALECTOR LLCInventors: Tina SCHWABE, Francesca AVOGADRI-CONNORS, Helen LAM, Ilaria TASSI, Seung-Joo LEE, Arnon ROSENTHAL
-
Publication number: 20190315858Abstract: The invention is generally directed to methods and compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a TREM2 protein, e.g., a mammalian TREM2 and/or human TREM2. The methods provided herein find use in preventing, reducing risk, or treating an individual having dementia, frontotemporal dementia, Alzheimer's disease, Nasu-Hakola disease, or multiple sclerosis.Type: ApplicationFiled: April 11, 2019Publication date: October 17, 2019Applicant: ALECTOR LLCInventors: Kate Monroe, Tina Schwabe, Francesca Avogadri-Connors, Ilaria Tassi, Helen Lam, Arnon Rosenthal
-
Publication number: 20190174730Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from TREM1, TREML1, TREM2, TREML2, and TREML4, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human TREM immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human TREM repertoire.Type: ApplicationFiled: December 12, 2018Publication date: June 13, 2019Applicant: Alector LLCInventors: Ilaria Tassi, Asa Abeliovich, Seung-Joo Lee, Arnon Rosenthal, Tina Schwabe